Acute Idiopathic Polyneuritis & Idiopathic Thrombocytopenic Purpura
JAMA 243:256-257, Gross,P.T., 1980
Neurological Events Reported after COVID-19 Vaccines: An Analysis of Vaccine Adverse Event Reporting System
Ann Neurol 91:756-771, Frontera, J.A.,et al, 2022
An 8-Year-Old with Acute Onset Ataxia
Neurol 99:305-310, McLaren, J.R.,et al, 2022
Guillain-Barre Syndrome Associated with JEV Infection
NEJM 383:1188-1190, Wang, G.,et al, 2020
GQ1b-Seronegative Miller Fisher Syndrome Associated with Pembrolizumab
J Neuro-Ophthal 39:394-396, Green, K.E.,et al, 2019
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Acute Onset of Diplopia in Pregnancy
Neurol 91:e180-e184, Munro, Z. & Fernandez, D., 2018
Acute Demyelinating Polyneuropathy Caused by Nivolumab in a Man with Metastatic Non-Small Cell Lung Cancer
J Gerontol Geriatr Res 5:3, Sabeeh-Ur-Rehman, B. & Bhaumik, S., 2016
Neurological, Respiratory, Musculoskeletal, Cardiac and Ocular Side-Effects of Anti-PD-1 Therapy
Eur J Cancer 60:210-225, Zimmer, L.,et al, 2016
Paraparetic Guillain-Barre Syndrome
Neurol 82:1984-1989, Van Den Berg, B.,et al, 2014
Neurological Immune-Related Adverse Events of Ipilimumab
Pract Neurol 13:278-280, Bot, I.,et al, 2013
Evidence-based Guideline: Intravenous Immunoglobulin in the Treatment of Neuromascular Disorders
Neurol 78:1009-1015, Patwa,H.S.,et al, 2012
Guillain-Barre Syndrome
NEJM 366:2294-2304, Yuki, N. & Hartung, H.P., 2012
Spectrum of Paraneoplastic Disease Associated With Lymphoma
Neurol 76:705-710, Briani,C.,et al, 2011
Guillain-Barre Syndrome
BMJ 337:227-231, Winer,J.B., 2008
Monoclonal Antibody Therapies and Neurologic Disorders
Arch Neurol 65:1162-1165, Novack,J.C.,et al., 2008
Guillain-Barre Syndrome
Lancet 366:1653-1666, Hughes,R.C. &Comblath,D.R., 2005
Intravenous Immunoglobulin in Autoimmune Neuromuscular Diseases
JAMA 291:2367-2375, Dalakas,M.C., 2004
Practice Parameter:Immunotherapy for Guillain-Barre Syndrome, Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 61:736-740, Hughes,R.A.C.,et al, 2003
Outcome in Severe Pediatric Guillain-Barre Syndrome after Immunotherapy or Supportive Care
Neurol 52:1494-1497, Graf,W.D.,et al, 1999
Intravenous Immunoglobulin Treatment in Neurologic Disorders
Arch Neurol 56:1025-1027,1032, Sorensen,P.S., 1999
Is the Routine Use of Intravenous Immunoglobulin Treatment in Neurologic Disorders Justified?
Arch Neurol 56:1028-1032, Karussis,D.&Abramsky,O., 1999
Prognostic Factors of Guillain-Barre Syndrome After Intravenous Immunoglobulin or Plasma Exchange?
Neurol 53:598-604, Visser,L.H.,et al, 1999
Intravenous Immunoglobulin in the Treatment of Autoimmune Neuromuscular Diseases:Present Status and Practical Therapeutic Guidelines
Muscle & Nerve 22:1479-1497, Dalakas,M.C., 1999
CIDP:Clinical Features & Responses to Trtm in 67 Consecutive Pts with/without a Monoclonal Gammopathy
Neurol 48:321-328, Gorson,K.G.,et al, 1997
Intravenous Immune Globulin Therapy for Neurologic Diseases
Ann Int Med 126:721-730, Dalakas,M.C., 1997
Idiopathic Dysautonomia Treated with Intravenous Gammaglobulin
Lancet 347:28-29, Heafield,M.T.E.,et al, 1996
Reversible Encephalopathy with Cerebral Vasospasm in a Guillain-Barre Syndrome Patient Treated with Intravenous Immunoglobulin
Neurol 46:250-251, Voltz,R.,et al, 1996
Liver Function Disturbances in Guillain-Barre Syndrome:A Prospective Longitudinal Study in 100 Patients
Neurol 46:96-100, Oomes,P.G.,et al, 1996
Pilot Trial of Immunoglobulin Versus Plasma Exchange in Patients with Guillain-Barre Syndrome
Neurol 46:100-103, Bril,V.,et al, 1996
Childhood Leukemia:Central Nervous System Abnormalities During and After Treatment
AJNR 17:295-310, Chen,C-Y.,et al, 1996
Campylobacter Jejuni Infection and Anti-GM1 Antibodies in Guillain-Barre Syndrome
Ann Neurol 40:181-187, Jacobs,B.C.,et al, 1996
Intravenous Immunoglobulin Treatment of Neurological Disease
JNNP 60:359-361, Otten,A.,et al, 1996
Intravenous IgG in Guillain-Barre Syndrome
BMJ 313:376-377, Hughes,R.A.C., 1996
Lyme Radiculoneuritis Treated with Intravenous Immunoglobin
Neurol 46:1174-1175, Crisp,D.&Ashby,P., 1996
Acute Paresis of Extraocular Muscles Associated with IgG Anti-GQ Antibody
Ann Neurol 39:668-672, Yuki,N., 1996
Plasma Exchange and Intravenous Immunoglobulin Treatment of Neuromuscular Disease
Ann Neurol 35:260-268, Thornton,C.A.&Griggs,R.C., 1994
Treatment of Guillain-Barre Syndrome with High-Dose Immune Globulins-Combined with Methylprednisolone:Dutch Guillain-Barre Study Group
Ann Neurol 35:749-752, , 1994
Relapse in Guillain-Barre Syndrome after Treatment with Human Immune Globulin
Neurol 43:872-875, 8571993., Inrani,D.N.,et al, 1993
Human Immune Globulin Infusion in Guillain-Barre Syndrome:Worsening During & After Treatment
Neurol 43:1034-1036, 8571993., Castro,L.H.M.&Ropper,A.H., 1993
Intensive Management and Treatment of Severe Guillain-Barre Syndrome
Crit Care Med 21:433-446, Hund,E.F.,et al, 1993
A Randomized Trial Comparins Intravenous Immune Globulin and Plasma Exchange in Guillain-Barre Syndrome
NEJM 326:1123-1129, VanDerMeche,F.G.A.,et al, 1992
Immunologic Aspects of Neurological and Neuromuscular Diseases
JAMA 268:2918-2922, Zweiman,B.&Levinson,A.I., 1992
Treatment of Guillain-Barre Syndrome with Anti-T Cell Monoclonal Antibodies
JNNP 54:51-54, Feasby,T.E., 1991
Treatment Related Fluctuations in Guillain-Barre Syndrome after High-Dose Immunoglobulins or Plasma-Exchange
JNNP 54:957-960, Kleyweg,R.P.&van der Meche,F.G.A., 1991
Clinical Uses of Intravenous Immunoglobulins
Ann Int Med 112:278-292, Berkman,S.A.,et al, 1990
Benefit of Intravenously Administered Immune Serum Globulin in Patients with Guillain-Barre Syndrome
J Pediatr 116:141-144, Shahar,E.,et al, 1990
Clinicopath Conf
Hodgkin's Disease and Guillain Barre Syndrome, Case Record 39-1990, NEJM 323:895-908990., , 1990
Treatment of Guillain-Barre Syndrome with High-Dose Gammaglobulin
Neurol 38:1639-1641, Kleyweg,R.P.,et al, 1988